Incyte 

€65.42
101
+€5.4+9% Tuesday 13:36

统计数据

当日最高
65.42
当日最低
60.6
52周最高
-
52周最低
-
成交量
750
平均成交量
-
市值
12.65B
市盈率
160.15
股息收益率
-
股息
-

即将到来

收益

29Oct预期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
-1.82
-0.83
0.15
1.14
预期每股收益
1.05117
实际每股收益
1.07

人们还关注

此列表基于关注ICY.F的Stock Events用户的观察列表。这不是投资建议。

竞争者

这个列表是基于最近市场事件的分析。这不是投资建议。
AMGEN
AMGN
市值179.38B
Amgen在生物制药领域与Incyte竞争,专注于创新治疗领域,与Incyte的兴趣领域重叠,如肿瘤学和炎症学。
Gilead Sciences
GILD
市值98.35B
吉利德科学公司在肿瘤学和抗病毒药物等治疗领域与Incyte有着相似的业务,使它们成为癌症和其他治疗市场上的直接竞争对手。
Bristol-Myers Squibb
BMY
市值101.27B
Bristol Myers Squibb是一家全球生物制药公司,与Incyte竞争开发癌症治疗和免疫疗法,这也是Incyte重点投资的领域。
Merck
MRK
市值300.25B
默克是一家领先的制药公司,在肿瘤学领域与Incyte竞争,特别是在癌症治疗的开发和营销方面。
Novartis
NVS
市值244.75B
诺华与Incyte在多个领域竞争,包括肿瘤学和自身免疫性疾病,拥有广泛的产品组合,与Incyte的研发重点重叠。
Pfizer
PFE
市值164.39B
辉瑞是一家全球制药巨头,与Incyte竞争开发各种疾病的药物,包括癌症,这是Incyte的重点领域。
Roche
RHHBY
市值272.83B
罗氏控股与Incyte在肿瘤学和血液学领域竞争,专注于开发创新的癌症治疗方法。
Abbvie
ABBV
市值346.75B
AbbVie在免疫学和肿瘤学领域与Incyte竞争,尤其是在癌症和自身免疫性疾病治疗的开发方面。
Lilly(Eli) &
LLY
市值864.43B
Eli Lilly and Company在制药行业与Incyte竞争,重点关注肿瘤学等领域,这是Incyte业务的重要组成部分。
Regeneron Pharmaceuticals
REGN
市值130.59B
Regeneron Pharmaceuticals是生物制药领域的竞争对手,专注于肿瘤学和炎症性疾病等领域的创新治疗,与Incyte的研究和产品竞争直接相关。

分析师评级

70.5平均价格目标
最高估值为 €92。
来自过去6个月内的 13 个评级。这不是投资建议。
买入
31%
持有
62%
卖出
8%

关于

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
Show more...
首席执行官
Mr. Herve Hoppenot
员工
2524
国家
US
ISIN
US45337C1027
WKN
000896133

上市公司